Cell therapy co developing OpRegen in Ph 1/2 development for dry-AMD, OPC1 in Ph 1/2 development for spinal cord injury and VAC2 in Ph 1 development for NSCLC. Also developing Renevia as a cell delivery platform for HIV lipoatrophy (CE Mark response expected 2H19). Recently acquired Asterias Biotherapeutics (AST), spun off AgeX (AGEX) and currently hold 28% of OncoCyte (OCX).
100MM - 500MM
1010 Atlantic Avenue, Suite 102
Alameda, CA 94501-1147
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Hamptons CEO Roundtable 2019
August 15, 2019
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by